Q-omics provides the consensus-scored CYCS profile across patient tissues and cancer cell-line models. CYCS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CYCS is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CYCS RNA expression shows 18,717 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, THCA, and UVM as cancer lineages where CYCS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCS survival associations across molecular data types. CYCS RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCS RNA expression–survival associations across cancer types. High CYCS expression shows unfavorable associations in LUAD, HNSC, ACC, UVM, BRCA and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CYCS RNA expression.
This table summarizes CYCS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYCS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCS shows lower tumor expression in THCA, KIRC and COAD and higher tumor expression in LUAD, LIHC and HNSC. The THCA box plot shows higher CYCS RNA expression in normal versus tumor tissue (log2 FC = −1.205, t-test p < 0.001).
This table shows molecular features associated with CYCS in patient tissues and cancer cell lines. In patient samples, CYCS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYCS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
